Cancer Biomarkers Market: By Product (ELISA pair sets, RNA, Tumor suppressor, cDNA clone, & Others Based), By Type (Protein, Genetic, & Other Biomarkers) By Technology, By Tumor Type, By Application, & By Region-Forecast (2014-2021)

  • ID: 3920108
  • Report
  • 161 pages
  • IndustryARC
1 of 3
Cancer biomarkers are biological molecule found in blood, other body fluids, or tissues and are indicative of the presence of cancer in the body. Cancer biomarkers improves the cancer detection and facilitate high speed, non-invasive diagnosis using genomics and proteomics based tools. Globally, rising incidences of cancer, growing research on cancer biomarkers, and superior speed and accuracy of diagnosis are the prime growth drivers of global cancer biomarkers market. In addition, emerging economies such as China, India and others will create new opportunities for global cancer biomarkers market. However, higher capital investments, lack of reimbursement, and regulatory systems, and technical issues are the key restraints for global cancer biomarkers market.

This report identifies the global cancer biomarkers market size in for the year 2014-2016, and forecast of the same for year 2021. It also highlights the potential growth opportunities in the coming years, while also reviewing the market drivers, restraints, growth indicators, challenges, market dynamics, competitive landscape, and other key aspects with respect to global cancer biomarkers market.

Geographically North America dominated global cancer biomarkers market, followed by Europe due to growing government support for discovery and development of biomarkers, and rising usage of advanced omics technologies for the biomarker discovery. Asia Pacific is projected to have fastest growth, owing to rising incidences of cancer, and expansions by key market players in this region. Among all the applications, diagnostics segment has the highest market share in global cancer biomarkers market followed by drug discovery and development.

This report segments global cancer biomarkers market on the basis of product, technology, application, end-user, and regional market as follows:

Cancer Biomarkers Market, By Product: ELISA pair sets based, RNA based, Tumor suppressor based, cDNA clone based, and Others
Cancer Biomarkers Market, By Type: Protein Biomarkers, Genetic Biomarkers, and Others
Cancer Biomarkers Market, By Tumor Type: Colorectal Cancer, Cervical Cancer, Lung Cancer, Prostate Cancer, Breast Cancer, and Others
Cancer Biomarkers Market, By Technology: Immunoassays, Omics Technologies, Cytogenetics, Imaging Technologies, and Bioinformatics
Cancer Biomarkers Market, By Application: Drug Discovery and Development, Diagnostics, Risk Assessment, Prognostics, and Others
This is report has been further segmented into major regions, which includes detailed analysis of each region such as: North America, Europe, Asia-Pacific (APAC), and Rest of the World (RoW) covering all the major country level markets in each of the region

This report identifies all the major companies operating in the cancer biomarkers market. Some of the major companies’ profiles in detail are as follows:

Abbott Laboratories
Affymetrix, Inc.
Illumina, Inc.
Qiagen N.V.
Roche Diagnostics Ltd.
Please Note: The report is to be delivered in 1-2 working days after an order is placed.
Note: Product cover images may vary from those shown
2 of 3
1. Cancer Biomarkers Market Overview
2. Executive Summary
3. Cancer Biomarkers Market Landscape
3.1. Market Share Analysis
3.2. Comparative Analysis
3.3. Product Benchmarking
3.4. End User Profiling
3.5. Top 5 Financials Analysis
4. Cancer Biomarkers Market Forces
4.1. Drivers
4.1.1. Rising incidences of cancer
4.1.2. Growing research on cancer biomarkers
4.1.3. Superior speed and accuracy of diagnosis
4.2. Restraints
4.2.1. Higher capital investments
4.2.2. Lack of reimbursement and regulatory systems
4.2.3. Technical issues
4.3. Opportunities
4.3.1. Developing countries
4.4. Challenges
4.5. Porter’s Five Forces Analysis
4.5.1. Bargaining Power of Suppliers
4.5.2. Bargaining Power of Buyers
4.5.3. Threat of New Entrants
4.5.4. Threat of Substitutes
4.5.5. Degree of Competition
5. Cancer Biomarkers Market, By Product
5.1. ELISA pair sets based
5.2. RNA based
5.3. Tumor suppressor based
5.4. cDNA clone based
5.5. Others
6. Cancer Biomarkers Market, By Type
6.1. Protein Biomarkers
6.2. Genetic Biomarkers
6.3. Others
7. Cancer Biomarkers Market, By Tumor Type
7.1. Colorectal Cancer
7.2. Cervical Cancer
7.3. Lung Cancer
7.4. Prostate Cancer
7.5. Breast Cancer
7.6. Others
8. Cancer Biomarkers Market, By Technology
8.1. Immunoassays
8.2. Omics Technologies
8.3. Cytogenetics
8.4. Imaging Technologies
8.5. Bioinformatics
9. Cancer Biomarkers Market, By Application
9.1. Drug Discovery and Development
9.2. Diagnostics
9.3. Risk Assessment
9.4. Prognostics
9.5. Others
10. Global Cancer Biomarkers Market, By Geography (2014-2021)
10.1. Europe
10.1.1. Germany
10.1.2. France
10.1.3. Italy
10.1.4. Spain
10.1.5. Russia
10.1.6. U.K.
10.1.7. Rest of Europe
10.2. Asia Pacific
10.2.1. China
10.2.2. India
10.2.3. Japan
10.2.4. South Korea
10.2.5. Rest of Asia-Pacific
10.3. North America
10.3.1. U.S.
10.3.2. Canada
10.3.3. Mexico
10.4. Rest of the World (RoW)
10.4.1. Brazil
10.4.2. Rest of RoW
11. Cancer Biomarkers - Market Entropy
11.1. Expansion
11.2. Technological Developments
11.3. Merger & Acquisitions, and Joint Ventures
11.4. Supply - Contract
12. Company Profiles (Top 10 Companies)
12.1. Abbott Laboratories
12.1.1. Introduction
12.1.2. Financials
12.1.3. Key Insights
12.1.4. Key Strategy
12.1.5. Product Portfolio
12.1.6. SWOT Analysis
12.2. Affymetrix, Inc.
12.2.1. Introduction
12.2.2. Financials
12.2.3. Key Insights
12.2.4. Key Strategy
12.2.5. Product Portfolio
12.2.6. SWOT Analysis
12.3. Illumina, Inc.
12.3.1. Introduction
12.3.2. Financials
12.3.3. Key Insights
12.3.4. Key Strategy
12.3.5. Product Portfolio
12.3.6. SWOT Analysis
12.4. Qiagen N.V.
12.4.1. Introduction
12.4.2. Financials
12.4.3. Key Insights
12.4.4. Key Strategy
12.4.5. Product Portfolio
12.4.6. SWOT Analysis
12.5. Roche Diagnostics Ltd.
12.5.1. Introduction
12.5.2. Financials
12.5.3. Key Insights
12.5.4. Key Strategy
12.5.5. Product Portfolio
12.5.6. SWOT Analysis
12.6. Agilent Technologies, Inc.
12.6.1. Introduction
12.6.2. Financials
12.6.3. Key Insights
12.6.4. Key Strategy
12.6.5. Product Portfolio
12.6.6. SWOT Analysis
12.7. Quest Diagnostics Inc.
12.7.1. Introduction
12.7.2. Financials
12.7.3. Key Insights
12.7.4. Key Strategy
12.7.5. Product Portfolio
12.7.6. SWOT Analysis
12.8. Merck & Co. Inc.
12.8.1. Introduction
12.8.2. Financials
12.8.3. Key Insights
12.8.4. Key Strategy
12.8.5. Product Portfolio
12.8.6. SWOT Analysis
12.9. Hologic, Inc.
12.9.1. Introduction
12.9.2. Financials
12.9.3. Key Insights
12.9.4. Key Strategy
12.9.5. Product Portfolio
12.9.6. SWOT Analysis
12.10. Becton, Dickinson and Company
12.10.1. Introduction
12.10.2. Financials
12.10.3. Key Insights
12.10.4. Key Strategy
12.10.5. Product Portfolio
12.10.6. SWOT Analysis

"*Financials would be provided on a best efforts basis for private companies"
13. Appendix
13.1. Abbreviations
13.2. Sources
13.3. Research Methodology
13.4. Expert Insights
Note: Product cover images may vary from those shown
3 of 3


4 of 3
Note: Product cover images may vary from those shown